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In vitro drug releaseAbstract Gelatin is an extensively studied biopolymer hydrogel drug carrier due to its biocompat-
ibility, biodegradability and non-toxicity of its biodegraded products formed in vivo. But with the
pristine gelatin it is difﬁcult to achieve a controlled and desirable drug release characteristics due to
its structural and thermal lability and high solubility in aqueous bioﬂuids. Hence it is necessary to
modify its solubility and structural stability in bioﬂuids to achieve controlled release features with
improved drug efﬁcacy and broader carrier applications. In the present explorations an effort is
made in this direction by cross linking gelatin to different extents using hitherto not studied
isocyanate terminated poly(ether) as a macrocrosslinker prepared from poly(ethylene glycol) and
isophorone diisocyanate in dimethyl sulfoxide. The crosslinked samples were analyzed for structure
by Fourier transform-infrared spectroscopy, thermal behavior through thermogravimetric analysis
and differential scanning calorimetry. The cross linked gelatins were biodegradable, insoluble and
swellable in bioﬂuids. They were evaluated as a carrier for in vitro drug delivery taking theophylline
as a model drug used in asthma therapy. The crosslinking of gelatin decreased the drug release rate
by 10–20% depending upon the extent of crosslinking. The modeled drug release characteristics
revealed an anomalous transport mechanism. The release rates for ampicillin sodium, 5-ﬂuorouracil
and theophylline drugs in a typical crosslinked gelatin carrier were found to depend on the solubility
and hydrophobicity of the drugs, and the pH of the ﬂuid. The observed results indicated that this
material can prove its mettle as a viable carrier matrix in drug delivery applications.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The use of natural polymers such as gelatin (Young et al.,
2005), starch (Al-Karawi and Al-Daraji, 2010), chitosan
(Sinha et al., 2004; Bertoldo et al., 2007; Subramanian and
Vijayakumar, 2011), etc., as carriers in controlled drug delivery
applications is gaining importance because of their inherent
biocompatibility, biodegradability and biosafety (Young
et al., 2005). But a common disadvantage of such natural
polymers is their structural and thermal lability (Bigi et al.,
2001), which require improvement for controlled and targeted
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44 V. Vijayakumar, K. Subramaniandrug release applications. In this context, gelatin a well-known
and widely used biopolymer drug carrier has been chosen for
improving its drug release characteristics, because the high sol-
ubility, and poor mechanical and thermal stability of gelatin
under physiological conditions may not facilitate a desirable
sustained drug release. Hence it is necessary to modify itsNH CH C
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Figure 2 Crosslinking reactiosolubility in bioﬂuids to have a controlled release characteristic
with improved drug efﬁcacy and broader application as a car-
rier for a wide range of drugs. Several chemical modiﬁcations
such as crosslinking with formaldehyde (Digenis et al., 1994),
glutaraldehyde (Narayani and Panduranga Rao, 1996),
1,4-diisocyanato butane, hexamethylene diisocyanate,2 C NH
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Table 1 Composition of reaction ingredients for cross linked gelatin samples.
Cross linked gelatin Feed composition for prepolymer (ICTPE) (mole) Gelatin (g) Insoluble crosslinked gelatin yield (g)
PEG-600 (·103) IPDI (·103)
GEPI-5 0.4483 0.8966 2 1.925
GEPI-10 0.896 1.793 2 2.125
GEPI-20 1.799 3.599 2 2.325
GEPI-30 5.398 5.398 2 2.401
Table 2 Intensity ratio of IR absorption peaks at 1705 and 3285 cm1 in crosslinked gelatins.
Polymer sample h1705 cm1 (A) h3285 cm1 (B) A/B
GEPI-10 1.3 1.8 0.72
GEPI-10Da 1.5 2 0.75
GEPI-20 0.9 2 0.45
GEPI-20Da 1.1 1.7 0.64
GEPI-30 0.9 2 0.45
GEPI-30Da 1.2 1.8 0.66
A and B, Peak heights at 1705 and 3285 cm1 (Fig. 3), respectively.
a Degraded cross linked gelatin in SIF at 37 C.
Diisocyanate mediated polyether modiﬁed gelatin drug carrier for controlled release 451,12-diisocyanto dodecane, 1,3-butadiene diepoxide, and
1,2,7,8-diepoxyoctane (Patil et al., 2000), grafting (Patil
et al., 2000; Curcio et al., 2010, Va´zquez et al., 1995), etc. have
been reported in the literature to bring down its solubility and
rate of biodegradation and to improve the thermal and
mechanical stability under in vivo conditions. Majority of these
crosslinkers are reported to be toxic in nature either inherently
or by its toxic degradation products formed in vivo. In the pres-
ent study gelatin crosslinking was performed using the isocya-
nate terminated oligomeric poly(ethylene glycol) (PEG-600)
prepared by reacting isophorone diisocyanate (IPDI) and
PEG-600 to modify the gelatin properties because of the less
toxicity of IPDI compared to other diisocyanate crosslinkers
(Ferreira et al., 2007; Guelcher et al., 2005) and biocompatibil-
ity of PEG. Moreover, the PEG spacer may minimize the loss
in the ﬂexibility and swellability of the gelatin after crosslink-
ing. The study also involved the evaluation of the crosslinked
gelatin as a drug carrier through in vitro release studies in sim-
ulated biological ﬂuids taking theophylline as a model drug.
Structural effects of drugs on their release characteristics were
also tested with a typical crosslinked gelatin carrier taking the
drugs 5-ﬂuorouracil, ampicillin sodium salt and theophylline
as speciﬁc examples.
2. Experimental
2.1. Materials
The gelatin (GE, intrinsic viscosity 0.135 dl/g in water at
30 C) used in the study was a gift sample from Sterling Bio-
tech, Ooty, India. It was dried under vacuum at 60 C to re-
move moisture for seven days. Dimethyl sulfoxide (DMSO)
and dichloromethane (SRL Mumbai) were dried overnight
on anhydrous Na2SO4, distilled and used. Isophorone diisocy-
anate (IPDI, Sigma–Aldrich 99%), poly(ethylene glycol)-600
(PEG-600), disodium hydrogen orthophosphate and monoso-
dium dihydrogen orthophosphate, (SD ﬁne), hydrochloricacid, sodium chloride, acetone and methanol (Rankem) were
used as received. Simulated gastric ﬂuid (SGF, pH 1.2) and
simulated intestinal ﬂuid (SIF, pH 7.2) were prepared as per
United States Pharmacopeia (USP) (Patel and Amiji, 1996).
The drugs ampicillin sodium salt (AMP, antibiotic to treat
gram+ve and gram ve, organisms), theophylline (THP, used
in respiratory therapy) and 5-ﬂuorouracil (5 FU, anti-meta-
bolic drug, used in cancer chemotherapy) (Himedia) were used
as received. The structures of these drugs are shown in Fig. 1.
2.2. Synthesis of isocyanate terminated polyether (ICTPE)
Isocyanate terminated poly(ethylene glycol) was prepared by
reacting PEG-600 and IPDI (mole ratio 1:2) at 35 C in
DMSO solution in a 100 ml three necked RB ﬂask provided
with nitrogen inlet and magnetic stirrer, kept in a thermostated
(35 C) water bath. In a typical reaction, 0.8966 · 103 mole of
IPDI was dissolved in 5 ml of DMSO and added to
0.4483 · 103 mole of PEG-600 under vigorous stirring. The
stirring was continued for 24 h to facilitate the completion of
the isocyanate terminated poly(ether) formation.
2.3. Synthesis of ICTPE modiﬁed gelatin
Dry gelatin (2 g) was taken in a three necked RB ﬂask
equipped with dry nitrogen inlet, mechanical stirrer and addi-
tion funnel and dissolved by adding 20 ml of dry DMSO at
35 C and stirred overnight under nitrogen atmosphere to
complete the dissolution. To this solution, the above synthe-
sized prepolymer ICTPE in DMSO was added drop wise over
a period of 2 min. A sudden build-up in viscosity was observed
followed by gelatin due to polyurea forming reaction. The
reaction was continued for another hour to facilitate its com-
pletion. The yellowish transparent ICTPE cross linked gelatin
gels with different degrees of cross linking levels designated as
GEPI-5, GEPI-10, GEPI-20 and GEPI-30 (Table 1) were syn-
thesized using different proportions of gelatin and ICTPE. The
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Figure 3 4 FT-IR spectra of, (a) PEG, (b) IPDI, (c) GE, (d)
GEPI-5,(e) GEPI-10 (f) GEPI-30, (g) GEPI-10D, (h) GEPI-20D
and (i) GEPI-30D in KBr matrix.
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Figure 4 Effect of weight% of ICTPE on residual amino group
in cross linked gelatin (A) and% acetone insoluble fraction of aged
cross linked gelatin (B) in SGF (a) and SIF (b), and biodegrada-
tion of GEPI-5 and GEPI-20 with time (C) in SGF and SIF.
46 V. Vijayakumar, K. Subramaniancrosslinked gelatin polymer gel thus obtained was removed,
cut into small pieces and soaked in dichloromethane (100 ml)
with mechanical stirring for 5 h to remove the hoarded DMSO
and unreacted IPDI if any present in the gel. Then it was im-
mersed in boiling distilled water for 3 h to remove unreacted
gelatin and subsequently Soxhlet extracted using water/ethanol
(1:1) mixture for 48 h and dried at 60 C under reduced pres-
sure to constant weight. The dried polymer was kneaded in a
mortar and pestle to make ﬁne powder and sieved in 150 mi-
cron sieves (Jayant Test Sieves, India), vacuum dried at
60 C for 4 h and stored in air tight PP/HDPE storage vials un-
til further usage. The structure of crosslinked gelatin was
analyzed by FT-IR.
2.4. Characterization
2.4.1. Extent of cross linking by ninhydrine method
Since the number of free hydroxyl and carboxyl groups present
in gelatin are very much less compared to the free amino
groups, as a good approximation it may be assumed reason-
ably that majority of IPDI and gelatin reaction is due to the
urea forming reaction between amino and isocyanate groups
of gelatin and IPDI respectively. The extent of cross-linking
in gelatin sample was determined by ninhydrine assay of free
amino groups through absorbance measurement at 570 nm be-
fore and after cross-linking with IPDI, taking glycine as the
reference standard (Yuan et al., 2007). Ninhydrine solution
was prepared by mixing the solution A, containing 1.05 g of
citric acid, 10 ml of 1.0 M NaOH and 0.04 g SnCl2Æ2H2O, di-
luted to 25 ml using deionized H2O with the solution B having
1 g ninhydrine dissolved in 25 ml 2-methoxy ethanol. The
mixed solutions were stirred for 45 min and stored in an amber
colored bottle.2.4.2. Swelling studies
Swelling studies were performed in simulated bioﬂuids (SGF
and SIF) at 37 C by keeping a known weight (100 mg) of
cross linked copolymer compressed(5 ton, KBr press) pellet
in a stainless steel (SS) cylindrical mesh (30 mm dia; 50 mm
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Figure 5 TGA (A) and DTG (B) traces of, (a) GE, (b) GEPI-5,
(c) GEPI-10 and (d) GEPI-20.
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Diisocyanate mediated polyether modiﬁed gelatin drug carrier for controlled release 47height) immersed in 20 ml of SGF or SIF taken in a 25 ml bea-
ker and allowed to swell. The weights of the swelled copoly-
mers at predetermined time intervals were calculated after
wiping the mesh containing the swelled polymer with a tissueTable 3 Onset degradation temperature data for gelatin and
ICTPE crosslinked gelatins.
Polymer Onset degradation temperature (C)
GE 370
GEPI-5 340
GEPI-10 325
GEPI-20 319paper. Then, the average degree of swelling (=(Wt–W0)/W0,
where Wt and W0 are the weights of the polymer after and be-
fore swelling) for the triplicate experiments was plotted against
time to get the swelling proﬁle.
2.4.3. Degradation studies
Degradability of the cross linked gelatin was tested in SGF and
SIF by immersing 0.15 g of polymer in 20 ml each at 37 C in
separate stoppered conical ﬂasks and kept in a shaker (10 rpm)
incubator for two weeks. Then the residual polymers in the
bioﬂuids at different time intervals were recovered through
precipitation using ice cold acetone, dried and weighed. The
residual polymer weights were then compared with the extent
of cross linking in terms of ICTPE taken and number of amino
groups reacted/or left behind after the reaction. The residual
polymers recovered from degraded GEPI-10, GEPI-20 and
GEPI-30 in bioﬂuids were designated as GEPI-10 D, GEPI-
20D and GEPI-30 D, respectively.
2.4.4. Fourier infrared (FT-IR) spectrum
FT-IR spectra of gelatin and modiﬁed gelatin were recorded
on JASCO FT-IR-460 in KBr pellet for the spectral range
400–4000 cm1with 2 cm1 resolution by accumulating 48
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Figure 6 DSC thermograms of, (A) gelatin and crosslinked
gelatins and (B) drugs and tablets.
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48 V. Vijayakumar, K. Subramanian2.4.5. X-ray diffraction (XRD)
X-ray diffractogram was recorded on Shimadzu XRD-6000
diffractometer with Cu Ka radiation operated at the voltage
and current values of 40 kV and 30 mA respectively for the
2h values in the range 5–45at a scan speed of 5/min.
2.4.6. Thermo gravimetry (TG)
TG/DTG studies were performed on TGA Q500 V20.10 Build
36 with a sample size of 1.5–3.5 mg under nitrogen atmosphere
at a heating rate of 20 C/min for the temperature range from
ambient to 800 C.
2.4.7. Differential scanning calorimetry (DSC)
DSC thermograms of the cross linked polymers were recorded
on Perkin Elmer Pyris 6DSC model in nitrogen atmosphere at
a heating rate of 10 C/min.
2.4.8. In-vitro drug dissolution studies
Compressed tablets of dia, 13 mm and thickness, 0.5 mm
made by compressing (5 ton) a homogeneous mixture of
drug(15 mg) and polymer(200 mg) were used for in vitro
drug dissolution studies in an USP apparatus Type II
(Veego Model VDA-6DR) in SGF and SIF at 37 C by
embarking the tablet inside the SS basket immersed in a
thermo stated and stirred (50 rpm) biological ﬂuid. The tab-
lets maintain their integrity and shape during swelling for a
period of time >5 h. The amount of drug released was
estimated UV-spectrophotometrically (Perkin Elmer Lamda
35 UV–VIS spectrophotometer) by withdrawing aliquots of
sample from the drug release vessel at a time interval of
15 min up to 1 h followed by 30 min by measuring its
absorbance values at 270 nm (Sloan et al., 1998). An average
of three identical measurements were taken to determine the
amount of drug released for a given set of experimental
conditions. To maintain a constant volume of the experi-
mental solution a volume equivalent of aliquot sample as
incubated fresh ﬂuids was added to the solution after each
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Figure 7 XRDs of gelatin (GE (a)) and cross linked gelatins
GEIP-5 (b), GEIP-10 (c) and GEIP-20 (d).3. Results and discussion
3.1. Cross linking of gelatin with ICTPE
Formation of ICTPE from IPDI and PEG-600 via the ure-
thane reactions and the subsequent crosslinking of gelatin
using ICTPE via the urea and urethane link forming reactions
in DMSO are illustrated in Fig. 2.
3.2. FT-IR analysis
FT-IR spectra of PEG, IPDI, gelatin and ICTPE cross linked
gelatins (GEPI-5, GEPI-10 and GEPI-30) are shown in
Fig. 3. The absorption peaks around 1652 and 1561 cm1
(Fig. 3(d–f)) were assigned to urea amide (CO–NH) band (I)
and (II) respectively (Shen et al., 2009). The peak at
2259 cm1 (Fig. 3b) characteristic of isocyanate group
(–NCO) was absent in Fig. 3 (d–f)) indicating the absence of
unreacted –NCO groups in crosslinked gelatin. The peak at
1082 cm1 (Fig. 3d) was attributed to the C–O–C linkage of
PEG segment. The absorption peak at 1705 cm1 was assigned
to the>C‚O stretching of urethane group(Yilgor et al., 2000).
The IR spectra also revealed that the intensity of the C–H0 30 60 90 120 150 180 210
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Figure 8 Swelling proﬁles of GEPI-5 (a), GEPI-10 (b), GEPI-20
(c) and GEPI-30 (d) in SGF (A) and SIF (B) at 37 C.
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Figure 9 Release proﬁles of THP with carriers, (a) GEPI-5, (b)
GEPI-10, (c) GEPI-20 and (d) GEPI-30 in SGF (A) and SIF (B) at
37 C.
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Figure 10 Release proﬁles of drugs THP, AMP and 5 FU in
SGF and SIF at 37 C with GEPI-30 as carrier.
Diisocyanate mediated polyether modiﬁed gelatin drug carrier for controlled release 49stretching (2949 cm1) (Shen et al., 2009) increased with the in-
creased concentration of ICTPE in the feed.
3.3. Degree of cross linking and degradability
With the increased content of ICTPE in the crosslinking reac-
tion mixture, the residual amino group in the cross linked poly-
mer decreased (Fig. 4A) indicating participation of more
amino groups in urea link formation. During ageing of the
crosslinked polymer in SGF and SIF, the ﬂuids become more
viscous and this was more likely attributed to the dissolution
of oligomers formed through biodegradation. Moreover, the
acetone insoluble polymer fraction recovered from these ﬂuids
using the precipitant acetone at different immersion times de-
creased both in SGF and SIF supporting the biodegradation
of the polymer. An increase in the weight of residual acetone
insoluble polymer was observed with the extent of cross linking
(Fig. 4B) indicating enhanced resistance toward biodegrada-
tion with increased crosslink density. The degradation proﬁles
of GEPI-5 and GEPI-20 in SGF and SIF with respect to time
displayed in. Fig. 4C revealed that the amount of the polymerdegraded decreased with increased percentage of crosslinker in
the monomer feed. The degradation was also supported by the
variation in IR absorption peak intensity ratio ðh1705 cm1=
h3285 cm1 Þ (Fig. 3(d) and (g), (e) and (h), (f) and (i) and Table 2)
of peaks at 1705 cm1 (urethane carbonyl) and 3285 cm1
(amide N–H stretching) (Yilgor et al., 2000) after immersing
in bioﬂuids. If there was no degradation, the intensity ratio
of the above peaks would have remained the same as that in
the original sample.
3.4. TGA/DTG
The TG/DTG traces of gelatin and cross linked gelatin shown in
Fig. 5 indicated that the thermal stability of gelatin decreased
after cross linking and this wasmore likely attributed to the low-
er thermal stability of urea linkage compared to peptide bond
(Awad and Wilkie, 2010). Onset degradation temperature data
for gelatin and ICTPE crosslinked gelatins are given in Table 3.
The major degradation of gelatin starts at 220 C and ends at
370 C and the initial weight loss below150 C was attributed
to the loss of moisture and other volatile impurities if any. The
cross linked gelatin showed three step degradations around
270, 321 and 330 C, unlike gelatin which degraded by a single
step route. The weight loss around 270–275 C was due to
degradation initiated via urea linkage (Awad and Wilkie,
2010). The residual weights at 850 C for GEPI-5, GEPI-10
and GEPI-20 were 12%, 10% and 5%, respectively implying
decreased residual weight with increased crosslinker level in
the feed. This may be attributed to more number of degradation
sites in the polymer due to introduction of more urea linkages.
The weight loss in the temperature range 190–240 C was
assigned to the degradation of hydrolytic by-products of IPDI
(amines and polyureas) (Berthold et al., 1996). Comparison of
the TG traces of gelatin and ICTPE crosslinked gelatin implied
that the degradation step in the temperature range of 270–
450 C was due to the degradation of gelatin backbone.
3.5. DSC trace analysis
The DSC traces of gelatin and ICTPE crosslinked gelatin
(Fig. 6A) showed random glass transitions below the degradation
50 V. Vijayakumar, K. Subramaniantemperature due to crosslinking via urea and urethane links’
formation (Fig. 2). The endotherm around 100 C in all the
samples was due to residual moisture loss. The origin of endo-
therm around 270 C in the ICTPE crosslinked gelatin may be
more likely due to the endothermic degradation of hydrolyzed
products of –NCO (Ofner and Bubnis, 1996) which was also
revealed in the TG trace (Fig. 5) as a weight loss around
270 C. The inﬂexion point around 165 C in the cross linked
gelatin (GEPI-10) may be attributed to glass transition as there
was no weight loss around this temperature in TG (Fig. 5). The
broad endotherm beyond 280 C in all the samples was as-
cribed to the massive endothermic degradation of polyurea
and peptide links. Comparison of DSC thermograms of
THP(c) and 5 FU (a) with those of their corresponding
tablets in GEPI-10 matrix (GEPI-10F(b) &GEPI-10T(d)
(Fig. 6B)indicted that the melting points of THP (273 C)
and 5 FU (281 C, which overlapped with the broad endother-
mic matrix degradation temperature range of 250–320 C and
hence was not visible as a sharp melting endotherm(Fig. 6B(b))
have been reduced signiﬁcantly in the tablet and the melting
endotherms were very broad unlike the sharp of melting endo-
therms of pure drugs. These observations tend to reveal that
there may be a broad range of polymer matrix–drug physical
interaction and the drugs are compatible with the matrix.
AMP is unstable near its melting point (215 C) (Ampicillin
Sodium Salt, 2012) and its DSC thermogram showed a broad
exotherm around 235 C (Fig. 6B(e)). This exotherm was more
prominent in the ampicillin tablet (Fig. 6B(f)) which may be
due to the matrix effect.
3.6. XRD analysis
XRD patterns of gelatin and ICTPE crosslinked gelatin
(Fig. 7) revealed a broad peak at 2h value around 22 and this
remains nearly the same both in virgin and cross linked gelatin.
This implied the increased amorphous character with cross-
linking. It is anticipated that the increased amorphous charac-
ter may decrease the chain ﬂexibility and hence may increase
drug release rate if diffusion is the drug release mechanism.
3.7. Matrix swelling
Increasing the concentration of ICTPE in the reaction recipe
decreased the degree of swelling of ICTPE crosslinked gelatin
both in SIF and SGF (Fig. 8) due to increased extent of cross
linking. Since gelatin is highly soluble in water, the measure-
ment of its correct degrees of swelling at different instants of
time was difﬁcult and hence its swelling proﬁle is not displayed
in Fig. 8.
3.8. In vitro drug release study
The in vitro release proﬁles of theophylline in SGF and SIF are
given in Fig. 9. The release rate with gelatin carrier was greater
in SGF than in SIF perhaps due to enhanced swellability of
carrier in SGF due to protonation of gelatin via its amino
groups. During the initial 20 min of release, the quantum of
drug released in SIF was nearly independent of extent of de-
gree of cross linking due to poor swelling, and the cross linking
effect on theophylline release rates was noticed only after
25 min. But in SGF the inﬂuence of degree of crosslinkingon release rates was different right from the start of dissolution
experiment, and this was more likely attributed to greater swel-
lability of matrix in SGF than in SIF for the reason mentioned
earlier. The release rate decreased with increased cross linking
in spite of the increased amorphous character of the carrier
(Fig. 7). If swelling-diffusion is the mechanism of drug release,
the increased amorphous character may enhance release rate
which was not observed. These facts corroborate that the de-
creased release rate with enhanced cross linking may be not
only due to poor swelling but also due to decreased degrada-
tion rate. Hence, the mechanism of release may be interpreted
in terms of competitive relaxational and diffusional mecha-
nisms (Urdahl and Peppas, 1988) and carrier degradation. This
was supported by the degradation of carrier in SGF and SIF
(Fig. 4B). But for a release period of 5 h the matrix degrada-
tion may not be prominent. Hence the mechanism of release
may be predominantly through segmental relaxation and dif-
fusion. Even though increased cross linking decreased the
swelling properties of the carrier signiﬁcantly, the drug release
rate was decreased to a lesser extent again substantiating the
fact that diffusion may not be the exclusive mechanism of drug
release. Typical release proﬁles of ampicillin sodium salt and
5 FU in SGF at 37 C were also made by the spectrophotomet-
ric estimations of the released drugs at 254 and 266 nm
(Sunshine 1982; Huang et al., 2010), respectively with GEPI-
30 carrier and are displayed in Fig. 10 along with theophylline
release curve. The higher release rates for ampicillin sodium
salt and 5 FU compared to that of theophylline may be due
to their high water solubility, and slow release of theophylline
may be due to its more hydrophobicity compared to the other
two drugs.
3.9. Drug release mechanism
Drug release was modeled as per the following empirical ki-
netic equation (Curcio et al., 2010).
Mt=M1 ¼ ktn
where Mt/M1 is the fractional release at time t, k is rate con-
stant and ‘n’ is the diffusional exponent. The exponent ‘n’ pro-
vides an indication of the release mechanism and generally
ranges from 0.5 to 1. It was calculated from the slope of the
logarithmic plot (i.e., ln(Mt/M1) vs. ln(t)) after linearizing
the above kinetic expression. A value of n= 0.5 corresponds
to a Fickian diffusion, whereas a value in the range 0.6–0.8
indicates anomalous transport as there exists an inﬂuence of
swelling and/or erosion (Curcio et al., 2010). In the present
study for the IPDI cross linked gelatin the experimental
n-values were in the range of 0.6–0.8 revealing an anomalous
transport mechanism (non-Fickian) for the drug release. The
anomalous mechanism may also be attributed to the compet-
ing release through matrix degradation. However, its contribu-
tion may be very less for an initial release period of 5 h or less.4. Conclusions
Gelatin with polyether urea crosslinks was synthesized using
the isocyanate terminated polyether prepared from IPDI and
PEG-600, and its thermal stability, in vitro swellability, degra-
dability and drug release characteristics as a carrier matrix
were evaluated using theophylline as a model drug. Its
Diisocyanate mediated polyether modiﬁed gelatin drug carrier for controlled release 51in vitro swellability and drug release were decreased with in-
creased extent of crosslinking. The release rate was more in
SGF than in SIF. Comparison of typical release proﬁles for
ampicillin sodium salt, theophylline and 5-ﬂuorouracil in a
typical carrier GEPI-30 indicated only marginal differences
in release rates and this may be due to the minor variation
in the hydrophobicity and solubility of drugs and their physi-
cal interaction with the matrix, and the lengthy chain of cross-
linker, ICTPE. Modeling of the drug release indicated an
anomalous transport mechanism. The cross linked gelatin is
biodegradable in SIF and SGF and the biodegradability de-
creased with increased degree of cross linking. The degradabil-
ity in SGF and SIF may also contribute for the drug release
rate. But the release mechanism for the initial periods of 5 h
or less seemed to be non-Fickian. The results suggested that
the cross linked gelatin might be a promising vehicle for sus-
tained release preparations in oral therapy. This material
may also be used in tissue engineering as scaffold in medical
ﬁeld because of its biocompatibility and biodegradability.Acknowledgment
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